
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 12, 2016

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-35547
(Commission
File Number)

36-4392754
(IRS Employer
Identification No.)

**222 Merchandise Mart Plaza, Suite 2024,
Chicago, Illinois 60654**
(Address of Principal Executive Offices) (Zip Code)

Registrant's Telephone Number, Including Area Code: (312) 506-1200

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 7.01. Regulation FD Disclosure

On January 12, 2016, Allscripts Healthcare Solutions, Inc. (the “Company”) will present at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, California. A copy of the Company’s presentation is furnished as Exhibit 99.1. The Company intends to use this presentation at other investor conferences.

The information furnished pursuant to this Item shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Copy of Allscripts Healthcare Solutions, Inc. presentation slides

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 12, 2016

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

By: /s/ Brian P. Farley

Brian P. Farley

Senior Vice President and General Counsel

EXHIBIT INDEX

Exhibit No.	Description
99.1	Copy of Allscripts Healthcare Solutions, Inc. presentation slides

January 12 2016

34th Annual J.P. Morgan
Healthcare Conference
Allscripts Investor Presentation

Disclaimer

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding Allscripts Healthcare Solutions, Inc.'s (the "Company's") financial estimates and anticipated cost savings.

These forward-looking statements are based on the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results could differ from those set forth in the forward-looking statements, and reported results should not be considered an indication of future performance. Certain factors that could cause the Company's actual results to differ materially from those described in the forward-looking statements can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2014. The Company's Annual Report and its other filings are available at our website (<http://investor.allscripts.com>) and on the Securities and Exchange Commission's website (<http://www.sec.gov>). Allscripts does not undertake to update the forward-looking statements to reflect the impact of circumstances or events that may arise after the date of the forward-looking statements.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of the Company or its subsidiaries. Other company and product names featured in this presentation may be the trademarks of their respective owners.

Non-GAAP Financial Measures

This presentation includes references to non-GAAP revenue, gross profit, gross margin, adjusted non-GAAP SG&A, net income, including non-GAAP earning per share basis and Adjusted EBITDA and free cash flow, which are also considered non-GAAP financial measures under Section 101 of Regulation G under the Securities Exchange Act of 1934, as amended. Each of these measures adjusts for certain items and are not considered financial measures under generally accepted accounting principles in the United States ("GAAP").

- Non-GAAP revenue consists of GAAP revenue as reported and adds back deferred revenue and other adjustments recorded for GAAP purposes.
- Non-GAAP gross profit consists of GAAP gross profit as reported and adds back deferred revenue and other adjustments booked for GAAP purposes and excludes acquisition-related amortization, stock-based compensation expense, and non-recurring expenses and transaction-related costs. Non-GAAP gross margin consists of non-GAAP gross profit as a percentage of non-GAAP revenue, as defined above.
- Adjusted non-GAAP selling, general and administrative expenses consists of GAAP selling, general and administrative expenses as reported and adds back severance and other costs, MyWay product consolidation expense, transaction-related costs and stock-based compensation expense and adds back incentive compensation, non-cash depreciation related to the acquisition of a new ERP system and acquired selling, general and administrative associated with the acquisition of dBMotion and JarDogs in February 2013.
- Adjusted EBITDA is a non-GAAP measure and consists of GAAP net income (loss) as reported and adjusts for: tax provision (benefit); interest expense and other income, net; stock-based compensation expense; depreciation and amortization; deferred revenue and other adjustments; non-recurring and transaction-related costs; and non-cash asset impairment charges.
- Non-GAAP net income consists of GAAP net income/(loss) as reported, and adds back deferred revenue and other adjustments, acquisition-related amortization, stock-based compensation expense, non-recurring expenses and transaction-related costs, non-cash charges to interest expense and other, and non-cash asset impairment charges, in each case net of any related tax effects. Non-GAAP net income also includes a tax rate alignment adjustment.
- Non-GAAP earnings per share consists of non-GAAP net income, as defined above, divided by weighted shares outstanding – diluted in the applicable period.
- Free cash flow is calculated based on GAAP cash flows provided by operating activities in the applicable period, net of capital expenditures and capitalized software costs.

Management also believes that non-GAAP revenue, gross profit, gross margin, Adjusted SG&A, Adjusted EBITDA, net income and earnings per share as well as free cash flow provide useful supplemental information to management and investors regarding the underlying performance of Allscripts business operations. Acquisition accounting adjustments made in accordance with GAAP can make it difficult to make meaningful comparisons of the underlying operations of the business without considering the non-GAAP adjustments provided and discussed herein. Management also uses this information internally for forecasting and budgeting, as it believes that these measures are indicative of core operating results. In addition, management may use non-GAAP revenue, gross profit and gross margin to measure achievement under Allscripts stock and cash incentive compensation plans. Note, however, that non-GAAP revenue, gross profit and gross margin are performance measures only, and they do not provide any measure of cash flow or liquidity. Non-GAAP financial measures are not in accordance with, or an alternative for, measures of financial performance prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with Allscripts results of operations as determined in accordance with GAAP. Investors and potential investors are encouraged to review the reconciliation of non-GAAP financial measures with GAAP financial measures contained within this presentation as well as within the company's press release dated November 5, 2015. These are available on Allscripts investor relations website (<http://www.investor.Allscripts.com>).

Contents

- Who We Are
- Industry
- Position and Strategy
- Financial Model
- Appendix/GAAP-Non-GAAP Reconciliations

WHO WE ARE

A global leader in healthcare
technology

About Allscripts

Our Company



NASDAQ: MDRX
IPO: 1999

Global HQ: Chicago, IL

FY 2014 Revenue: \$1.4B

Our Team



~7,000 team associates

Veteran executive leadership

12 countries incl. Australia,
Canada, Israel & UK

Allscripts Facts

5.7M+
PATIENTS
USE PORTAL

12M+
REFERRALS

400K+
CONNECTED TO
FOLLOWMYHEALTH

180K
PHYSICIANS

45K+
PHYSICIAN
PRACTICES

2,500
HOSPITALS

17K
POST-ACUTE
FACILITIES

An **OPEN** Connected
Community of Health

Why Allscripts?

What We Do



EHR/RCM

- Recurring revenue
- Services
- Global



Population Health Management

- Secular trend
- Innovation/investment



Connect Consumers

- Engagement
- Analytics



Precision Medicine

- Future of healthcare
- Proteomics/Genomics

Investment Considerations

- Comprehensive solutions across healthcare globally
- Growing bookings, recurring revenue
- Significant, sustainable operating leverage
- Accelerating cash flow growth
- Compelling valuation

INDUSTRY

Industry Challenges



**Aging population
with increasing
chronic disease**



Service demand increasing
Access to care challenges
Unsustainable cost trajectory



**Improve quality
while lowering
costs**

Source: Health Affairs 2013

Permanent Reimbursement Shift Underway

VOLUME

- Fragmented providers and payments
- No uniform quality
- Fees for performing services
- Demand increasing
- Referral loss


VALUE

- Collaboration, connectivity
- Clinical and financial analysis
- Optimize outcomes
- Accountable care

Source: HFMA "Value in Healthcare: Current State & Future Directions" June 2011, Allscripts

Strategic Imperative for Healthcare

Shift from reactive care to proactively and predictably managing populations



Note: Data excludes the uninsured and VA populations, year = 2012. | Source: Oliver Wyman analysis, Kaiser, CMS, Census Bureau, CDC.

ALLSCRIPTS POSITION AND STRATEGY



Allscripts Evolution



Allscripts Value Proposition



Combine all patient data in one place



Provide insights to prioritize interventions & drive predictability



Coordinate care across community



Engage patients in managing their care and health



Enable change at the point of care with a Community Aware EHR

Execute across the healthcare continuum



Ambulatory

Physician Practices
Clinics
...



Acute

Hospitals
Health Systems
...



Post Acute

Home Care
Long-Term Care
...



Community

Pharmacies
Labs
Specialists
In- and out-of-network
physicians
...



Consumer

Patient Engagement
Technologies
Portals
Wearable Tech
Personalized Medicine
...

Business Momentum Globally



560

New clients
added 2015 YTD
(3Q15)

#1
KLAS

Global EMR**

#1
EMR

BlackBook*

EMRAM
Stage 7

achieved by the
National Institutes of
Health, using Sunrise in
2015

800+
SOURCE
SYSTEMS

across the globe connected
to dbMotion

CXO Next
Innovation Award

from Microsoft to
Allscripts Chief Innovation
Officer in 2015

29
New Sunrise
Facilities

added since 2013

*2015 #1 Academic Medical Center & Large Inpatient EHR, #1 Communications & Connectivity, #1 Results Review & Decision Support | **2014 Best in KLAS Global EMR

Interoperability Leadership: Allscripts Developer Program (ADP)



APPS

~**130** certified 3rd
party apps/devices



PARTNERS

2100 developer
accounts



USERS

>**1 billion** data shares
2013 through 2015
>**150%** growth in 2015


Notes:

Allscripts ADP Store: www.store.allscripts.com

Data share equals specific information called from an Allscripts solution, can be single or multiple variable in a single call.

The Future: Precision Medicine

Percentage of the patient population for which a particular drug in a class is ineffective, on average



Source: Brian B. Spear, Margo Heath-Chiozzi, Jeffrey Huff, "Clinical Trends in Molecular Medicine," Volume 7, Issue 5, 1 May 2001, pages 201-204.

FINANCIAL MODEL



Creating Shareholder Value

Growth Pillars

EHR/core system replacements

**Population health management
(PHM)**

Recurring services

Global EHR/systems

RESULTS

29 new Sunrise facilities added

5% revenue growth in PHM YTD

14% recurring services growth YTD

**Two major academic center trusts
added in Q3 and Q4 2015**

Note: YTD refers to nine months ended September 30, 2015. New Sunrise facilities announced through December 31, 2015.

Copyright © 2016 Allscripts Healthcare Solutions, Inc.

 Allscripts

22

Creating Shareholder Value

Execution Playbook

Maximize client retention

Generate consistent results

Increase operational efficiency

Invest in R&D/Innovation

RESULTS

Support & maintenance stable


Bookings +13% YTD

Expect to finish 2015 w/ adjusted non-GAAP SG&A reduction of >\$50mm v. 2012 (>15%)

- ~16% revenue YTD invested in gross R&D (+\$170m)
- **PLUS**~\$500mm of strategic investments since '13 =
- **>\$1.1b in cumulative R&D and investments since 2013**

Note: YTD refers to nine months ended September 30, 2015. Adjusted non-GAAP SG&A totaled \$332 mm in 2012. See reconciliation of non-GAAP metrics in the appendix of this presentation.

Sales Activity (Bookings) = The best measure of momentum




- Record third quarter \$272m
- Three consecutive records
- Balance btwn software & services

13%

Bookings Growth YTD

Note: YTD refers to nine months ended September 30, 2015.

Contract Backlog




- Backlog at record high
- Steady growth in software

\$3.6b


September 30, 2015

2015 Results YTD (two stories)



- **76%** of revenue recurring
- Anticipate ending 2015, w/ anniversary of non-recurring revenue declines, to allow recurring revenue momentum to show through

Expanding Non-GAAP Gross Margins



- 2/3rd driven by software; 1/3rd services
- Major step forward fixing services margins
- Software margins above historical average due to support efficiencies and better mix

46.4% in Q3

Non-GAAP Gross Margin

YTD Results

Through September 30, 2015

\$128m

Cash Flow From Operations (>2x y/y)

\$177m

Adjusted EBITDA
(+21% y/y)

\$62m

Non-GAAP Net Income
(+58% y/y)

Outlook

Q4 2015

- Expect all-time record quarterly bookings (prior \$327m Q4 2011)
 - A fourth consecutive record for quarterly bookings
 - Will report Q4 and full year audited results on February 18, 2016
-

2016

- Non-GAAP earnings per share growth of 20-30% v. 2015 expected results
- Full year guidance specifics to be provided with results on February 18th

Note: Based on disclosure of January 12, 2016. This presentation is not an affirmation of prior financial guidance. For a reconciliation of GAAP and non-GAAP results, please see the reconciliation of non-GAAP financial measures with GAAP financial measures contained within this presentation as well as within the company's press release dated November 5, 2015. These are available on Allscripts investor relations website on (<http://www.investor.allscripts.com>).

Valuation Considerations

Non-GAAP Earnings Per Share Growth

Stocks	2016 P/E*	2016 Growth (E)*	P/E /2016(E) Growth*
MDRX	25x	26%	.97x
Two largest public HIT peers	25x and 91x	14% and 31%	1.8x and 2.9x

Free Cash Flow

Stocks	Enterprise Value/ TTM FCF*
MDRX	30x
Two largest public HIT peers	90x and NM**

*Note: Please see appendix in this presentation for a complete reconciliation of valuation calculations, including industry peers. Peer data listed in descending order by market capitalization.

**NM = negative free cash flow for the applicable period.

Investment Considerations

- Comprehensive solutions across healthcare globally
- Growing bookings, recurring revenue
- Significant, sustainable operating leverage
- Accelerating cash flow growth
- Compelling valuation

APPENDIX – Non-GAAP Reconciliations

Reconciliations: Non-GAAP Adjusted SG&A

Allscripts Healthcare Solutions, Inc.
Supplemental Data Sheet
Selling, General and Administrative Expenses
(In millions)
(unaudited)

	2012	2013	2014	2015
	Full Year	Full Year	Full Year	Nine Months YTD 2015
GAAP selling, general and administrative expenses	\$384.4	\$419.6	\$358.7	\$259.7
Severance and other costs	(18.9)	(39.0)	(6.3)	(22.8)
Litigation	-	-	-	-
MyWay product consolidation	-	(11.3)	(6.4)	-
Transaction-related costs	(3.6)	(8.0)	(3.7)	(0.1)
Stock-based compensation expense	(25.9)	(23.0)	(25.4)	(15.9)
Non-GAAP selling, general and administrative expenses	\$336.0	\$338.3	\$316.9	\$221.0
Incentive compensation	(2.0)	(14.1)	(3.9)	(3.2)
Non-cash depreciation related to new ERP system	(0.7)	(5.0)	(7.6)	(5.7)
Acquired selling, general & administrative expenses (dbMotion, Jardogs & Oasis)	-	(9.6)	(13.8)	(14.4)
Adjusted non-GAAP selling, general and administrative expenses	\$333.2	\$309.6	\$291.6	\$197.7

Reconciliations: Recurring/Non-Recurring Revenue

Allscripts Healthcare Solutions, Inc.
Supplemental Financial Information
(In millions)
(unaudited)

Non-GAAP Revenue	2014				2015				YTD '15/'14
	Q1	Q2	Q3	Total	Q1	Q2	Q3	Total	% Chg
Software Delivery, Support & Maintenance									
Subscription & recurring transactions	73.6	73.0	73.4	220.0	78.0	79.2	77.3	234.6	7%
Support & maintenance	117.9	113.6	117.5	349.0	119.4	116.3	116.9	352.6	1%
System sales & other	38.1	38.7	37.6	114.4	30.2	37.0	36.5	103.7	-9%
Total Software Delivery, Support & Maintenance	229.6	225.3	228.5	683.4	227.6	232.5	230.7	690.8	1%
Recurring managed services	58.7	57.8	58.8	175.2	60.1	67.8	71.0	198.9	14%
Other client services	56.5	70.7	60.4	187.7	46.9	51.4	52.8	151.1	-19%
Total Client Services	115.2	128.5	119.2	362.9	107.0	119.2	123.8	350.0	-4%
Total non-GAAP revenue	344.8	353.8	347.7	1,046.3	334.6	351.7	354.5	1,040.8	-1%
Revenue Mix									
Recurring revenue	73%	69%	72%	71%	77%	75%	75%	76%	6%
Non-recurring revenue	27%	31%	28%	29%	23%	25%	25%	24%	-16%
	100%	100%	100%	100%	100%	100%	100%	100%	

Reconciliations: Non-GAAP Gross Margin

Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information
(In millions)
(unaudited)

	2014			2015		
	Q1	Q2	Q3	Q1	Q2	Q3
Software Delivery, Support & Maintenance						
Gross profit, as reported	131.2	121.9	129.9	130.6	135.2	138.6
Deferred revenue and other adjustments	2.2	0.3	0.4	(0.0)	0.0	0.0
Acquisition-related amortization	8.8	8.6	9.0	9.1	9.2	9.1
Stock-based compensation expense	0.4	0.6	0.3	1.1	1.2	1.0
Non-recurring expenses and transaction-related costs	1.9	0.9	0.8	0.0	0.0	0.0
Non-GAAP gross profit	144.4	132.3	140.5	140.8	145.6	148.7
Client Services						
Gross profit, as reported	7.0	18.1	1.5	(0.8)	8.4	14.8
Deferred revenue and other adjustments	2.3	2.2	1.9	0.0	0.0	0.0
Stock-based compensation expense	0.9	1.5	1.0	1.4	1.3	0.8
Non-recurring expenses and transaction-related costs	0.0	0.7	2.0	0.0	0.0	0.0
Non-GAAP gross profit	10.2	22.5	6.4	0.6	9.7	15.6
Non-GAAP Gross Profit						
	Q1	Q2	Q3	Q1	Q2	Q3
Software Delivery, Support & Maintenance	144.4	132.3	140.5	140.8	145.6	148.7
Client Services	10.2	22.5	6.4	0.6	9.7	15.6
Total non-GAAP gross profit	154.7	154.8	146.9	141.4	155.3	164.3
Non-GAAP Gross Margin						
Software Delivery, Support & Maintenance	62.9%	58.7%	61.5%	61.9%	62.6%	64.5%
Client Services	8.9%	17.5%	5.4%	0.6%	8.2%	12.6%
Total non-GAAP gross margin	44.8%	43.8%	42.3%	42.3%	44.2%	46.4%

Reconciliations: Adjusted EBITDA

Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information - Adjusted EBITDA
(In millions)
(unaudited)

	Nine Months Ended September 30,	
	2015	2014
Net loss, as reported	(\$18.4)	(\$64.3)
Deferred revenue and other adjustments	0.0	9.3
Depreciation and amortization	124.5	131.6
Stock-based compensation expense	28.7	32.2
Non-recurring expenses and transaction-related costs	23.4	21.4
Non-cash asset impairment charges	0.3	2.1
Interest expense and other, net (a)	13.4	11.5
Equity in net earnings of unconsolidated investments	1.3	-
Tax provision/(benefit)	4.2	2.8
Adjusted EBITDA	177.4	146.6
Adjusted EBITDA attributable to non-controlling interest	0.5	0.0
Adjusted EBITDA, net of non-controlling interest	\$176.9	\$146.6
<i>Adjusted EBITDA margin (b)</i>	<i>17%</i>	<i>14%</i>

(a) Interest expense and other, net has been adjusted from the amounts presented in the statements of operations in order to remove the amortization of the fair value of the cash conversion option embedded in the 1.25% Cash Convertible Notes and deferred debt issuance costs from interest expense since such

(b) Adjusted EBITDA margin is calculated by dividing adjusted EBITDA, net of non-controlling interest by total non-GAAP revenue.

Reconciliations: Non-GAAP Net Income

Allscripts Healthcare Solutions, Inc.
Condensed Non-GAAP Financial Information
(In millions, except per share amounts)
(unaudited)

	Nine Months Ended September 30,	
	2015	2014
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders, as reported	(\$18.5)	(\$64.3)
Deferred revenue and other adjustments	0.0	6.1
Acquisition-related amortization	30.2	31.7
Stock-based compensation expense	18.7	20.9
Non-recurring expenses and transaction-related costs	15.2	14.5
Non-cash asset impairment charges	0.2	1.4
Non-cash charges to interest expense and other	6.2	4.9
Equity in net earnings of unconsolidated investments	1.1	0.0
Tax rate alignment	9.2	24.3
Non-GAAP net income attributable to Allscripts Healthcare Solutions, Inc.	\$62.3	\$39.5

Reconciliations: Allscripts Free Cash Flow

Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information: Free Cash Flow

(In millions)

(unaudited)

	Nine Months Ended September 30, 2015
Net cash provided by operating activities	128.3
Cash flows from investing activities:	
Capital expenditures	(14.2)
Capitalized software	(32.7)
Cash and cash equivalents, end of period	<u><u>\$81.4</u></u>

Reconciliations: Trailing Twelve Month Free Cash Flow

(In millions)

	Three Months Ended December 31, 2014	Nine Months Ended September 30, 2015	Twelve Months Ended September 30, 2015
Allscripts			
Net cash provided by operating activities	\$51.50	\$128.30	\$179.80
Cash flows from investing activities:			
Capital expenditures	(5.7)	(14.2)	(19.9)
Capitalized software	(12.4)	(32.7)	(45.1)
Free Cash Flow	\$33.4	\$81.4	\$114.8
Cerner			
Net cash provided by operating activities	\$223.45	\$594.43	\$817.88
Cash flows from investing activities:			
Capital expenditures	(76.2)	(255.4)	(331.6)
Capitalized software	(47.0)	(204.7)	(251.7)
Free Cash Flow	\$100.2	\$134.3	\$234.5
AthenaHealth			
Net cash provided by operating activities	45.0	102.9	147.9
Cash flows from investing activities:			
Capital expenditures	(12.2)	(77.7)	(90.0)
Capitalized software	(25.0)	(65.1)	(90.1)
Free Cash Flow	\$7.8	(\$39.9)	(\$32.1)

Source: Allscripts Investor Relations/Company reports

Reconciliations: Valuation Data

Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information: Valuation Data
(In millions) Except price, multiples and per share amounts

	Price 12/6/2015	Market Capitalization	Cash & ST Securities	Total Debt	Enterprise Value (EV)	TIM FCF	EV/PCF	2016 EPS (Est.)	2016 Price/Earnings (Est.)	Non-GAAP EPS Growth '16/'15 (Est.)	P.E./Growth
Allscripts (MDRX)	\$14.43	\$2,727	\$91	\$655	\$3,474	\$114.80	30.3 x	\$0.58	24.7	25.5%	0.97 x
Cerner (CERN)	58.16	19,897	465	631	\$20,992	234.5	89.5 x	2.36	24.7	13.8%	1.8 x
AthenaHealth (ATHN)	158.23	6,144	117	300	\$6,561	(32.1)	-204.2 x	1.74	90.8	31.3%	2.9 x

Note: Forecasts of non-GAAP earnings per share are based on NASDAQ First Call Consensus estimates. Other data sources from company reports or Reuters MarketScope Database.

January 12 2016

34th Annual J.P. Morgan
Healthcare Conference
Allscripts Investor Presentation
